ADVFN US – Market Content Editor
-
iPhone Sales Jump 15% Globally as Apple Leads in Chinese Market
Apple (NASDAQ:AAPL) saw a notable 15% increase in iPhone sales globally over April and May, reaching its strongest two-month performance since the onset of the COVID-19 pandemic, according to preliminary figures from Counterpoint Research. The tech giant secured the top spot in China’s smartphone market in May, underscoring a strong rebound in its two largest…
-
U.S. Stocks Recover From Early Weakness To Close Modestly High
Stocks recovered from an early move to the downside to move modestly higher over the course of the trading session on Thursday. With the turnaround, the major averages largely offset the pullback seen during Wednesday’s session, with the Dow and the S&P 500 rebounding to three-month closing highs. The S&P 500 (SPI:SP500) ended the day…
-
Gold Surpasses Euro as World’s Second-Largest Reserve Asset, Says ECB
Gold has overtaken the euro to become the world’s second most-held reserve asset—behind only the U.S. dollar—according to a new report from the European Central Bank (ECB). The shift reflects record central bank purchases and a sharp rise in gold prices. In its annual currency review, the ECB revealed that by the end of 2024,…
-
Philip Morris Stock Reaches Record High of $183.96 on Strong Growth Momentum
Philip Morris International Inc. (NYSE:PM) hit a new all-time high, with its shares climbing to $183.96, marking a significant achievement for the global tobacco leader. The company boasts a hefty market cap of $285 billion and maintains robust gross profit margins close to 66%, underscoring its dominant position in the market. Over the past year,…
-
Campbell Soup Shares Hit 52-Week Low Amid Market Challenges
Campbell Soup Company (NYSE:CPB) stock has fallen to a fresh 52-week low of $32.92, marking a sharp decline over the past year with a drop of 24.3%. This price level signals a notable pullback from previous highs, prompting analysts to weigh in with a range of price targets spanning from $32 to $62, suggesting the…
-
Planet Labs Shares Surge After Winning Major NATO Contract
Shares of Planet Labs PBC (NYSE:PL) jumped 7% following the announcement that the company has secured a substantial contract with NATO valued in the seven-figure range. Under this agreement, Planet Labs will provide cutting-edge daily monitoring and intelligence services. The deal involves deploying a specialized platform that integrates Planet Labs’ PlanetScope Broad Area Monitoring technology…
-
Palantir Pushes for Unified Federal Privacy Law in Congressional Submission
Palantir Technologies Inc. (NASDAQ:PLTR) has called on U.S. lawmakers to adopt a cohesive, nationwide data privacy and security framework, warning that the current patchwork of regulations could jeopardize civil liberties and complicate future oversight of emerging technologies, particularly artificial intelligence. In a formal response submitted in April to the House Energy and Commerce Committee’s Privacy…
-
Mattel Shares Tick Up After Announcing AI Partnership with OpenAI
Mattel Inc. (NASDAQ:MAT) saw its stock edge 1.2% higher following the announcement of a strategic alliance with OpenAI, aimed at developing artificial intelligence-driven products and experiences rooted in Mattel’s well-known brands. The collaboration brings together Mattel’s deep heritage in toy-making and family entertainment with OpenAI’s cutting-edge AI capabilities. The companies plan to co-create innovative, age-appropriate…
-
America’s Car-Mart Shares Surge Over 7% After Strong Q4 Earnings Beat
America’s Car-Mart Inc. (NASDAQ:CRMT) saw its stock climb 7.08% in pre-market trading on Thursday after the company reported stronger-than-expected financial results for the fourth quarter ending April 30, 2025. The used car retailer posted quarterly earnings per share (EPS) of $1.26, significantly outpacing analyst forecasts of $0.99. Revenue reached $370.2 million, beating the expected $360.02…
-
Merck Launches Final-Stage Trial of Dengue Vaccine for Children
Merck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric population, the company announced on Thursday. The trial aims to enroll around 12,000 participants aged 2 to 17, evaluating the effectiveness of a single dose of its V181 vaccine. The study will measure protection…